

--3. (Amended) The inhalable powder pharmaceutical composition according to claim 2, wherein the tiotropium salt is tiotropium chloride, tiotropium bromide, tiotropium iodide, tiotropium *p*-toluene sulfonate, or tiotropium methylsulfate.--

--4. (Amended) The inhalable powder pharmaceutical composition of claim 3, wherein the tiotropium salt is tiotropium bromide.--

--5. (Amended) The inhalable powder pharmaceutical composition according to claim 1, wherein the steroid is selected from the group consisting of: flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, GW 215864, KSR 592, ST-126, and dexamethasone.--

G2
--7. (Amended) The inhalable powder pharmaceutical composition according to claim 3, wherein the steroid is selected from the group consisting of: flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, GW 215864, KSR 592, ST-126, and dexamethasone.--

--8. (Amended) The inhalable powder pharmaceutical composition according to claim 3, wherein the steroid is selected from the group consisting of: flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, and dexamethasone.--

--9. (Amended) The inhalable powder pharmaceutical composition according to claim 1, wherein the weight ratios of the anticholinergic to the steroid are in the range of from 1:300 to 50:1.--

--10. (Amended) The inhalable powder pharmaceutical composition according to claim 7, wherein the weight ratios of the tiotropium salt to the steroid are in the range of from 1:250 to 40:1.--

G7
--15. (Amended) The inhalable powder pharmaceutical composition of claim 1, wherein the excipient has a maximum average particle size of up to 250 μm --

--16. (Amended) The inhalable powder pharmaceutical composition of claim 3, wherein the excipient has a maximum average particle size of up to 250 μm .--

--17. (Amended) The inhalable powder pharmaceutical composition of claim 4, wherein the excipient has a maximum average particle size of up to 250 μm .--

--18. (Amended) The inhalable powder pharmaceutical composition of claim 5, wherein the excipient has a maximum average particle size of up to 250 μm .--

--19. (Amended) The inhalable powder pharmaceutical composition of claim 15, wherein the excipient has a maximum average particle size of between 10 μm and 150 μm .--

Ag
--20. (Amended) The inhalable powder pharmaceutical composition of claim 16, wherein the excipient has a maximum average particle size of between 10 μm and 150 μm .--

--21. (Amended) The inhalable powder pharmaceutical composition of claim 17, wherein the excipient has a maximum average particle size of between 10 μm and 150 μm .--

--22. (Amended) The inhalable powder pharmaceutical composition of claim 18, wherein the excipient has a maximum average particle size of between 10 μm and 150 μm .--

--23. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 1.--

--25. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 3.--

Agf
--26. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 4.--

--27. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 5.--

--28. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 6.--

--29. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 7.--

--30. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 8.--

--31. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 9.--

--32. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 10.--

--33. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 19.--

44
--34. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 20.--

--35. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 15.--

--36. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 16.--

--37. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 17.--

--38. (Amended) A capsule containing the inhalable powder pharmaceutical composition according to claim 18.--

--39. (Amended) A pharmaceutical composition consisting essentially of:

G4

- (a) a tiotropium salt; and
- (b) a steroid,

wherein the pharmaceutical composition is in the form of an inhalable powder.--

--59. (Amended) A method of treating inflammatory or obstructive diseases of the respiratory tract in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition according to one of claims 1 to 12.--

G5

--60. (Amended) The method according to claim 59, wherein the disease is chronic obstructive pulmonary disease (COPD) or asthma.--

--63. (Amended) A kit comprising one or more unit dosage containers containing a pharmaceutical composition, each unit dosage container containing a pharmaceutical composition comprising:

G6

- (a) a tiotropium salt; and
- (b) a steroid,

each optionally together with a pharmaceutically acceptable excipient.--

--65. (Amended) A kit comprising:

G7

- (a) a first container containing a first pharmaceutical formulation comprising an tiotropium salt; and
- (b) a second container containing a second pharmaceutical formulation comprising a steroid,

each container each optionally further containing a pharmaceutically acceptable excipient.--
